Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, is presenting new prospective data on DetermaRx(TM) at the IASLC 2020 North America Conference on Lung Cancer taking place on October 22. Gavitt Woodard, M.D., assistant professor, Yale School of Medicine, and lead author on the study is presenting the data at the event hosted by the International Association for the Study of Lung Cancer. Per the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high-risk of recurrence despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. Medicare reimburses the test, which has seen rapid adoption in its first year of launch across 70 hospitals, including National Comprehensive Cancer Network (“NCCN”) and National Cancer Institute (“NCI”) centers. “We are very pleased that the initial data showing this test’s impact on cancer recurrence was maintained in the 250-patient expanded data set. This result establishes DetermaRx as the post-surgical treatment standard for patients diagnosed with NSCLC,” said Dr. Edgardo S. Santos, M.D., Florida Precision Oncology, a division of Genesis Care and an early adopter of the test. “The integration of testing for targeted therapy, including EGFR mutation status and chemotherapy selection by DetermaRx on the same sample, will enable oncologists to optimize and sequence treatment post-surgery. In my opinion, these two tests together close the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I would feel confident initiating chemotherapy, followed by targeted therapy for the EGFR-positive, DetermaRx high-risk patients I see in my practice.”
To view the full press release, visit https://ibn.fm/dbbL8
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The company’s proprietary tests and pharmaceutical company services aim to save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. Oncocyte’s tests and services present multiple opportunities to advance cancer care while driving the growth of its revenue. The company recently launched DetermaRx(TM), a treatment stratification test to identify early-stage lung cancer patients who are at high risk for cancer recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO(TM), a gene expression test that identifies patients who are more likely to respond to checkpoint inhibitor immunotherapies. The company also plans to launch Therasure(TM)-CNI MONITOR, a blood-based immune therapy monitoring test. Oncocyte’s pharmaceutical company services help pharmaceutical companies to develop new cancer treatments, many of which may be linked to Oncocyte’s diagnostic tests. For more information about the company, visit www.Oncocyte.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.